title: Systemic delivery of antiangiogenic adenovirus AdmATF induces liver resistance to metastasis and prolongs survival of mice.
abstract: Systemic administration of Ad5-based recombinant adenovirus leads to preferential transduction of the liver. Using this property, we have assessed the potential of venous viral injection to deliver a recombinant antiangiogenic adenovirus to treat cancer dissemination and improve survival. The results demonstrate that venous injection of adenovirus AdmATF, which encodes a secretable mouse ATF (amino-terminal fragment of urokinase) known to inhibit angiogenesis, suppressed angiogenesis induced by colon cancer metastasis growth in mice liver and improved survival. Nude mice were injected intravenously with 5 X 10(9) PFU of AdmATF and subsequently challenged after a 3-day interval by intrasplenically injected human colon carcinoma cells (LS174T, 3 x 10(6)) that home to liver. Microscopic inspection revealed that, within the AdmATF-pretreated mice (n = 8), the size and number of liver-metastasized nodules on day 30 were remarkably reduced (80% in number, p < 0.05) compared with control mice (n = 7) pretreated in parallel with a control adenovirus. Metastatic growth-related liver weight gain was also inhibited up to 90%. AdmATF-specific capability that offers liver resistance to the apparition and growth of liver metastasis was shown to correlate with the inhibition of peritumoral and intratumoral angiogenesis (reduced by 79%, p < 0.01 as shown by anti-vWF immunostaining of liver sections) and a twofold increase in tumor necrotic area and an eightfold increase in apoptotic tumor cell number. This protective effect was still observed when the mice were challenged 10 days after venous AdmATF injection (visible metastasis nodules: 6.3+/-3.1, n = 7 for control mice versus 2.7+/-2.9, n = 10 for treated mice, p < 0.05). More importantly, the mean survival has been prolonged from 45.1 days (n = 9) to 83.3 days (n = 10, p < 0.05). Altogether, the high efficacy, although transient, in this experimental mice model strongly advocates the plausibility of transforming the liver into a dissemination resistant organ by antiangiogenic gene therapy through systemic delivery approach.
authors.affiliation: CNRS UMR 1582/Rhône-Poulenc Rorer Gencell, Institut Gustave Roussy, Villejuif, France.
authors.forename: H
authors.initials: H
authors.lastname: Li
authors.forename: F
authors.initials: F
authors.lastname: Griscelli
authors.forename: F
authors.initials: F
authors.lastname: Lindenmeyer
authors.forename: P
authors.initials: P
authors.lastname: Opolon
authors.forename: L Q
authors.initials: LQ
authors.lastname: Sun
authors.forename: E
authors.initials: E
authors.lastname: Connault
authors.forename: J
authors.initials: J
authors.lastname: Soria
authors.forename: C
authors.initials: C
authors.lastname: Soria
authors.forename: M
authors.initials: M
authors.lastname: Perricaudet
authors.forename: P
authors.initials: P
authors.lastname: Yeh
authors.forename: H
authors.initials: H
authors.lastname: Lu
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D005260:Female; D007150:Immunohistochemistry; D008114:Liver Neoplasms, Experimental / Q000098:blood supply / Q000517:prevention & control* / Q000556:secondary*; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000235:genetics*; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000235:genetics; D016019:Survival Analysis; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000235:genetics
chemical_list: D010446:Peptide Fragments; D014568:Urokinase-Type Plasminogen Activator